Rx License-Rx

TAB-5061

Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties

One of the most challenging hurdles in creating safe and effective new medicines for many diseases is finding drugs that are effective without causing off-target cardiac issues, such as cardiac arrythmias. In collaboration with NIDA, scientists at NCATS have developed a series of novel and highly specific dopamine D3 receptor agonists and antagonists that have potential to target and treat Parkinson’s disease, Schizophrenia, Depression, and substance-use disorders including opioid addiction. Important features of these novel chemical compounds are that they exhibit favorable drug-like properties that are likely to make them successful drug candidates, and have reduced human ether-à-gogo-related gene (hERG) liability and effect on potassium channels, which suggests that the compounds may perform better as Dopamine D3 receptor agonists due to a lower propensity to create cardiac arrythmias. The novel compounds comprise potent and highly...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Neurology

Indication: Parkinson's disease

Modality: Biologic

Focus tags: Neurology

Technology tags: Biologic, Small Molecule

Mechanism:

Development stage: Preclinical

Patent status: Expired

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Neurology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with National Institutes of Health. The practical first use case is Parkinson's disease. Public description: One of the most challenging hurdles in creating safe and effective new medicines for many diseases is finding drugs that are effective without causing off-target cardiac issues, such as cardiac arrythmias. In collaboration with NIDA.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

High upside if the mechanism is measurable: Neurology is hard, but biomarkers, retinal surrogates, genetics, or target-engagement readouts can turn a vague CNS story into a fundable experiment.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

CNS translation is unforgiving: Brain exposure, target engagement, endpoint sensitivity, and placebo/noise risk can make development expensive without a biomarker-first plan.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Eli Lilly — Neurodegeneration leadership and biomarker-driven trial infrastructure. Biogen — CNS portfolio gap-filling and translational neurology focus. Roche — CNS diagnostics, biomarkers, and global development scale.

Development Strategy to Increase PoS

First indication: Parkinson's disease

Study design: Mechanism-first biomarker study before any broad symptomatic endpoint trial.

Key experiments Validate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy

Best next experiment: Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.